Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -8.69 SEK | -11.7% |
| 2022 | -7.78 SEK | 22.36% |
| 2021 | -10.02 SEK | -2.98% |
| 2020 | -9.73 SEK | -1005.68% |
| 2019 | -0.88 SEK | 65.35% |
| 2018 | -2.54 SEK | 12.71% |
| 2017 | -2.91 SEK | -238.37% |
| 2016 | -0.86 SEK | -11.69% |
| 2015 | -0.77 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -4.59 SEK | -1250.0% |
| 2024 Q2 | -0.88 SEK | 80.83% |
| 2023 Q1 | -3.49 SEK | -4950.65% |
| 2023 FY | - SEK | -11.7% |
| 2023 Q4 | -0.34 SEK | 89.17% |
| 2023 Q3 | -3.14 SEK | -83.63% |
| 2023 Q2 | -1.71 SEK | 51.0% |
| 2022 Q4 | -0.07 SEK | 59.35% |
| 2022 Q2 | -3.62 SEK | 8.35% |
| 2022 Q1 | -3.95 SEK | 5.73% |
| 2022 FY | - SEK | 22.36% |
| 2022 Q3 | -0.17 SEK | 95.3% |
| 2021 Q4 | -4.19 SEK | -3323.08% |
| 2021 Q1 | -2.51 SEK | 26.61% |
| 2021 Q2 | -3.20 SEK | -27.49% |
| 2021 FY | - SEK | -2.98% |
| 2021 Q3 | 0.13 SEK | 104.06% |
| 2020 Q1 | -1.65 SEK | -450.0% |
| 2020 Q2 | -1.50 SEK | 9.09% |
| 2020 FY | - SEK | -1005.68% |
| 2020 Q4 | -3.42 SEK | -23.47% |
| 2020 Q3 | -2.77 SEK | -84.67% |
| 2019 Q4 | -0.30 SEK | 76.92% |
| 2019 Q2 | 2.36 SEK | 493.33% |
| 2019 Q3 | -1.30 SEK | -155.08% |
| 2019 FY | - SEK | 65.35% |
| 2019 Q1 | -0.60 SEK | 4.76% |
| 2018 Q4 | -0.63 SEK | -40.0% |
| 2018 FY | - SEK | 12.71% |
| 2018 Q3 | -0.45 SEK | 16.67% |
| 2018 Q2 | -0.54 SEK | 53.04% |
| 2018 Q1 | -1.15 SEK | -88.52% |
| 2017 Q3 | -0.60 SEK | -9.09% |
| 2017 Q1 | -0.18 SEK | 0.0% |
| 2017 Q2 | -0.55 SEK | -205.56% |
| 2017 Q4 | -0.61 SEK | -1.67% |
| 2017 FY | - SEK | -238.37% |
| 2016 FY | - SEK | -11.69% |
| 2015 FY | - SEK | 0.0% |